In September 2023, the Food and Drug Administration approved momelotinib for the treatment of myelofibrosis (MF) with anemia, marking the fourth US regulatory approval of a Janus kinase (JAK) inhibitor for MF. A positive opinion from the European Medicines Agency followed in November 2023. Momelotinib’s ability to address splenomegaly, symptoms and anemia, including in thrombocytopenic patients (platelets ≥25 x 109/L), the ease of switching from ruxolitinib, and good tolerability …